Discover trends, market shifts, and competitive outlooks for the cancer cachexia industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Cancer Cachexia Market Size Shifted, And What Is the Outlook Through 2034?

The market size of cancer cachexia has seen significant growth in the past few years. It is projected to increase from $2.47 billion in 2024 to $2.62 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 6.4%. Factors such as enhanced comprehension of cancer biology, increasing cancer occurrence, an amplified aging demographic, an emphasis on individual-centric care, expansion of treatment alternatives, and heightened awareness within the healthcare provider community have all influenced the growth in the historic period.

Predictions suggest a robust expansion in the size of the cancer cachexia market over the coming years. It’s estimated to rise to $3.33 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. This growth forecast can be linked to an enhanced understanding of cachexia management, an increase in the elderly population, a higher acceptance rate of innovative therapeutic methodologies, an escalation in healthcare costs and beneficial governmental initiatives. Some key trends expected in the projected period include, augmenting efforts in research and development, an increase in therapeutic alternatives, an improvement in diagnosis rates, the acceptance of new treatment methods, and advancements in supportive healthcare strategies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Cancer Cachexia Market?

The cancer cachexia market is anticipated to expand due to the escalating occurrences of cancer. Cancer is a state characterized by the unchecked proliferation of abnormal cells in the body, which leads to tumor formation and interrupts regular bodily functions. Various factors are associated with cancer rates which include lifestyle modifications, environmental influences, an aging demographic, genetic susceptibility, enhanced detection methods resulting in earlier diagnosis, and heightened awareness urging more individuals to seek medical help. Progress in healthcare technology and a deeper comprehension of cancer and its complications have led to an increased diagnosis and reporting of cancer cachexia. Medical professionals are honing their skills in recognizing cachexia indicators, thus paving the way for quicker interventions and treatment initiation. For instance, the Australian Bureau of Statistics revealed in December 2023 that roughly 1.8% of the population or 456,200 individuals had cancer in Australia in 2022. Moreover, according to the National cancer institute in May 2024, it is projected that 2,001,140 new cancer cases will be diagnosed in the US in 2024, with anticipated death rates reaching 611,720. In 2022, close to 20 million new cases and 9.7 million deaths related to cancer occurred globally. By 2040, these numbers are expected to escalate to 29.9 million new cases annually and about 15.3 million deaths. Consequently, the rising prevalence of cancer is the propellant for the expansion of the cancer cachexia market.

Which Segments in the Cancer Cachexia Offer the Most Growth?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

What Are the Fastest-Growing Geographies in the Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Cancer Cachexia Industry?

Leading corporations in the cancer cachexia market are pushing boundaries by creating innovative medicinal solutions such as monoclonal antibodies for cachexia. This targeted treatment is designed to enhance body weight, muscle mass, and the overall life quality of individuals suffering from cancer cachexia. Monoclonal antibodies for cachexia focus on curbing factors resulting in muscle and weight reduction. For instance, Pfizer Inc., an American pharmaceutical giant, reported favorable results in September 2024 for their Phase 2 trial of Ponsegromab. This monoclonal antibody targets GDF-15, commonly found in patients with cancer cachexia. The trial revealed significant improvements in patients’ body weight, muscle mass, appetite, and physical activity, particularly in those administered with the 400 mg dose. Pfizer, encouraged by these positive results, intends to start registration-enabling studies by 2025 to further probe the efficacy of Ponsegromab in treating cancer cachexia.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

What Are the Key Elements That Define the Cancer Cachexia Market?

Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient’s quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model